Chiltern Expands European Operations with a New Office in the Netherlands
Chiltern International Limited (Chiltern), a global clinical contract research organization (CRO) announced that it has opened a new office in the Netherlands, appointing Angela Pasma as the Netherlands’ Country Manager.
Mr. Maurizio Passanisi, Chiltern’s Director of the Benelux Region commented, “The Netherlands continues to be an excellent place for clinical research with experienced investigators as well as highly regarded international key opinion leaders, all adhering to the highest of medical standards.
“Furthermore, in leading the growth of the Chiltern office in Leiden, Ms. Pasma brings a wealth of knowledge and experience to support Chiltern’s growing full service clinical and flexible staffing services in the region.”
Pasma added, “Having already cultivated positive relationships with clients and colleagues in the region, we look forward to expanding our operations here to further serve our clients’ needs. The Leiden office is well situated geographically to support this effort.”
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
